Gorilla adenoviral therapeutic cancer vaccine inducing HPV16/18-specific T-cell responses against E6/E7 antigens.
Replication-deficient gorilla adenoviral vector delivers HPV16/18 E6/E7 genes for in vivo antigen expression and presentation, inducing HPV16/18-specific CD8+ cytotoxic T-cell and CD4+ helper responses (and antibodies) that target and lyse E6/E7-expressing tumor cells.
YES
INDIRECT
Vaccine expresses HPV16 E7, priming HPV16 E7–specific CD8+ T cells that recognize E7 peptides on MHC I and lyse tumor cells via perforin/granzyme (with possible antibody-mediated effects).
Gorilla adenoviral therapeutic cancer vaccine inducing HPV16/18-specific T-cell responses against E6/E7 antigens.
Replication-deficient gorilla adenoviral vector delivers HPV16/18 E6/E7 genes for in vivo antigen expression and presentation, inducing HPV16/18-specific CD8+ cytotoxic T-cell and CD4+ helper responses (and antibodies) that target and lyse E6/E7-expressing tumor cells.
YES
INDIRECT
Therapeutic vaccine primes HPV18 E6–specific CD8+ T cells that recognize E6 peptides on MHC I and kill tumor cells via perforin/granzyme-mediated apoptosis (with CD4+ help).
Gorilla adenoviral therapeutic cancer vaccine inducing HPV16/18-specific T-cell responses against E6/E7 antigens.
Replication-deficient gorilla adenoviral vector delivers HPV16/18 E6/E7 genes for in vivo antigen expression and presentation, inducing HPV16/18-specific CD8+ cytotoxic T-cell and CD4+ helper responses (and antibodies) that target and lyse E6/E7-expressing tumor cells.
YES
INDIRECT
Vaccine-driven priming/expansion of HPV18 E7–specific CD8+ T cells; these CTLs recognize E7 peptides on MHC I of tumor cells and lyse them via perforin/granzyme pathways.
Autologous, lentivirally transduced chimeric antigen receptor (CAR) T-cell therapy engineered to express a CAR targeting glycoprotein non-metastatic B (GPNMB) on tumor cells, leading to CAR-mediated T-cell activation and cytotoxic killing of GPNMB-expressing cells.
Autologous T cells are lentivirally transduced to express a chimeric antigen receptor targeting GPNMB on tumor cells; CAR engagement activates the T cells and induces cytotoxic killing of GPNMB-expressing cells.
YES
DIRECT
CAR T cells bind GPNMB on target cells, become activated, and kill via perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).
Autologous T cells engineered ex vivo to express an HPV-specific T-cell receptor and reinfused as monotherapy to target HPV antigen–expressing tumors via TCR–MHC engagement and cytotoxic T-cell effector functions.
Autologous T cells are genetically engineered to express an HPV-specific T-cell receptor that recognizes HPV-derived peptides presented by HLA/MHC on tumor cells; TCR–MHC engagement activates cytotoxic T-cell signaling, leading to perforin/granzyme-mediated lysis and cytokine-driven killing of HPV antigen–expressing cancer cells.
YES
DIRECT
Engineered TCR-T cells recognize HPV E6/E7 peptide–HLA I complexes on tumor cells and kill them via cytotoxic T-cell effector functions (perforin/granzyme release and Fas–FasL–mediated apoptosis).